A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (NCT06602258)
A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Who can join: Review the eligibility criteria below.
Location: Banner Sun Health Research — Phoenix, Arizona
Age range: 50 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Banner Sun Health Research — Phoenix, Arizona
- Yale University School of Medicine — New Haven, Connecticut
- Bradenton Research Center — Bradenton, Florida
- K2 Medical Research — Clermont, Florida
- Advanced Clinical Research Network — Miami, Florida
- Renstar Medical Research — Ocala, Florida
- Progressive Medical Research — Port Orange, Florida
- Alzheimer's Research and Treatment Center-Stuart — Stuart, Florida
- Axiom Brain Health — Tampa, Florida
- Charter Research — The Villages, Florida
- Alzheimer's Research and Treatment Center — Wellington, Florida
- Columbus Memory Center, PC — Columbus, Georgia
- Hattiesburg Clinic — Hattiesburg, Mississippi
- Washington University School of Medicine — St Louis, Missouri
- Abington Neurological Associates LTD — Abington, Pennsylvania
- Neurology Clinic, P.C. — Cordova, Tennessee
- Kerwin Memory Center — Dallas, Texas
- National Clinical Research-Richmond, Inc — Richmond, Virginia
- National Center for Geriatrics and Gerontology — Ōbu, Aichi-ken
- National Hospital Organization Hiroshima-Nishi Medical Center — Ōtake, Hiroshima
- Keimei Memorial Hospital — Honjō, Miyazaki
- Rijikai Medical Corporation Katayama Medical Clinic — Kurashiki, Okayama-ken
- Tokyo Medical University Hospital — Shinjuku, Tokyo
- Keio University Hospital — Shinjuku, Tokyo
- Osaka Metropolitan University Hospital — Osaka,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.